[A new clinical trial in intravesical chemotherapy with instillation of peplomycin preparation as an emulsion in hydroxypropylcellulosum--preliminary study of patients with bladder tumor].
A new peplomycin (PEP) preparation was employed as an emulsion form in hydroxypropylcellulosum (HPC), which is familiar to have a liniment effect with a strong affinity to mucosa of the organ, in the management of 6 patients with bladder tumors. This emuled PEP in HPC (HPC-PEP) was instillated and thereafter, maintained for at least 2 hours at the frequency of once a week. All 6 patients had histopathologically confirmed T1 or T2 transitional cell carcinoma on biopsied specimen. The histological grading of the tumors were divided to 2 in G1, 3 in G2, and 1 in G3 of transitional cell carcinoma. The instillated agent was prepared from the mixture of 15 ml of 6% HPC and 90 mg PEP in 15 ml saline prior to use. A response to this treatment was evaluated primarily by cystoscopic findings and urine cytology 7 days after the instillation. In the present study, the beneficial effects of this treatment were briefly segregated into 4 categories as follows: excellent, good, fair and no responses were referred respectively to as complete eradication of visible tumor with negative urine cytology, a complete disappearance of the primary tumor with a persistent positive cytology, regression of the tumor size and no change of the primary tumor with sustained positive cytology. According to this estimation, 6 patients were categorized to 1 in excellent, 2 in good, 2 in fair and 1 in no responses to this new therapeutic preparation. Furthermore, urinary and serum levels of PEP were determined daily for 7 days after the instillation.(ABSTRACT TRUNCATED AT 250 WORDS)
Asakawa
M
M
Department of Urology, Osaka City University Medical School.
Maekawa
T
T
Mori
K
K
Ozaki
Y
Y
Horii
A
A
Yasumoto
R
R
Nishio
S
S
Maekawa
M
M
D000283:Administration, Intravesical; D000368:Aged; D000369:Aged, 80 and over; D001761:Bleomycin / Q000008:administration & dosage*; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy*; D002482:Cellulose / Q000008:administration & dosage / Q000031:analogs & derivatives*; D004655:Emulsions; D005260:Female; D006801:Humans; D008297:Male; D017663:Peplomycin; D014677:Pharmaceutical Vehicles; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy*
D004655:Emulsions; D014677:Pharmaceutical Vehicles; D001761:Bleomycin; D017663:Peplomycin; D002482:Cellulose; C008079:hydroxypropylcellulose